A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

"It's a new antibody that has a long half-life so each treatment can be prolonged."

Recent developments of interest in cardiovascular medicine

Question now is whether routine early treatment will translate to better clinical outcomes

Patient acceptance could be an advantage, researchers say

The powerful LDL-lowering agents aren't being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

AZD0780 — the first oral PCSK9 inhibitor — is lowering LDL cholesterol levels, report phase 1 trial investigators, but specialists are questioning the early findings.

Amgen's battle with Sanofi and Regeneron at the Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape US patent law and competition among companies that make antibody medicines.

PCSK9 inhibitors were associated with a lower risk for nonmelanoma skin cancer in older adults with atherosclerotic cardiovascular disease, in a retrospective cohort study.

Two Novo Nordisk programs in obesity and cardiovascular disease are on the chopping block, the company buried in its Q3 report, as CEO Lars Fruergaard Jørgensen plots a comeback in obesity. The chief executive is shutting down a Phase I obesity program dubbed LA-GDF15 and a PCSK9 inhibitor that just

Clinical trial affirms LDL reduction atop statins in pediatric familial hypercholesterolemia

NEW ORLEANS — Merck says sotatercept, Acceleron's lead drug before the Big Pharma bought it for $11.5 billion, significantly improved scores on an exercise test in a pivotal trial for pulmonary arterial hypertension (PAH). Now, Merck is working toward an FDA filing for what it hopes can one day be

A recent study showed a discrepancy between the target levels of LDL cholesterol stipulated in European guidelines and the levels achieved in clinical practice.

A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.

"Go early and go low" is an expert's response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.

Effects observed in inflammation and improved clinical outcomes

Recent developments of interest in cardiovascular medicine

Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its US debut in early 2022 with cautious uptake prospects.